It is noteworthy that although previous studies suggested that HR-negative patients tend to benefit from NAC, a study by Lisa et al[27] also concurrently pointed out that HR-positive BC patients tend to have a better prognosis and lower recurrence rate because of the use of aromatase inhibitors or selective ER modulators, such as Tamoxifen. The gene discussed is CYP19A1; the disease is breast cancer.